Bristol-Myers Presents 4-Year Data From Clinical Trials Of NULOJIXNASDAQThe company said that the results showed that the safety profile of NULOJIX through year 4 was consistent compared with results at year 3 with no new safety signals being identifie…
CA fines 13 hospitals for serious violations that led to patient injury or death – Legal Examiner
CA fines 13 hospitals for serious violations that led to patient injury or deathLegal ExaminerKaiser foundation Hospital – Oakland/Richmond in Oakland, CA – CDPH found that nursing staff failed to respond to cardiac paging system alarms, resulting …
Bristol-Myers Squibb Presents New 4-Year Data from the Long-Term Extensions of … – MarketWatch (press release)
Bristol-Myers Squibb Presents New 4-Year Data from the Long-Term Extensions of …MarketWatch (press release)Results showed that the safety profile of NULOJIX through year 4 was consistent compared with results at year 3 with no new safety signals bein…
Bristol-Myers Squibb Presents New 4-Year Data from the Long-Term Extensions of the BENEFIT and BENEFIT-EXT Clinical …
Bristol-Myers Squibb Company today announced new 4-year results from the long-term extensions of the BENEFIT and BENEFIT-EXT clinical trials of NULOJIX® , the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejectio…
Acetaminophen overdoses common cause of kids' liver failure – CBC.ca
CBC.caAcetaminophen overdoses common cause of kids' liver failureCBC.caAcetaminophen painkiller overdoses can cause life-threatening liver failure in children but the problem is avoidable, Canadian doctors say. "Acetaminophen overdose is a maj…
SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits … – SYS-CON Media (press release)
SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits …SYS-CON Media (press release)Come to New York and get yourself up to date with the Big Data revolution! As advanced data storage, access and analytics technologies aimed at…
SymBio Announces Results Presented at ASCO 2012 Evaluating … – Marketwire (press release)
SymBio Announces Results Presented at ASCO 2012 Evaluating …Marketwire (press release)SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits of TREAKISYM® (Bendamustine) in Combination With Rituximab in Patients …
SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits … – MarketWatch (press release)
SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits …MarketWatch (press release)TOKYO, Jun 04, 2012 (MARKETWIRE via COMTEX) — SymBio Pharmaceuticals Limited (jasdaq:4582) announced today that results from a multicenter, Phas…
Pharmacyclics® Announces Updated Results for BTK Inhibitor Ibrutinib (PCI … – MarketWatch (press release)
Pharmacyclics® Announces Updated Results for BTK Inhibitor Ibrutinib (PCI …MarketWatch (press release)Abstract # 6515: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab (BR) in patients with relapsed/ref…
What's Going Around: Chigger Bites – The Charlottesville Newsplex
What's Going Around: Chigger BitesThe Charlottesville NewsplexThey include: washing vigorously with soap and water, which removes the chigger, use over the counter steroid creams like hydrocortisone or calamine lotion, which can help with itching. …